Trial Profile
A phase I study of docetaxel (Taxotere), carboplatin, and gemcitabine (DoCaGem) as first-line therapy for patients with high-risk epithelial tumors of mullerian origin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2013
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Carboplatin
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 13 Oct 2005 New trial record.